Amphastar Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Amphastar Pharmaceuticals, Inc. (AMPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 565.77 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-02-26
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 565.77K shares, a 85.94% increase from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 304.27K shares, a 14.57% decline from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 356.18K shares, a 4.94% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 339.40K shares, a 43.51% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|
| 2025-12-31 | 565.77K shares 10-K · filed 2026-02-26 |
| 2024-12-31 | 304.27K shares 10-K · filed 2025-03-03 |
| 2023-12-31 | 356.18K shares 10-K · filed 2024-02-29 |
| 2022-12-31 | 339.40K shares 10-K · filed 2023-03-01 |
| 2021-12-31 | 600.80K shares 10-K · filed 2022-03-11 |
| 2020-12-31 | 733.57K shares 10-K · filed 2021-03-15 |
| 2019-12-31 | 443.08K shares 10-K · filed 2020-03-16 |
| 2018-12-31 | 439.98K shares 10-K · filed 2019-03-15 |
| 2017-12-31 | 679.02K shares 10-K · filed 2018-03-14 |
| 2016-12-31 | 732.02K shares 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |